Substance
ID:349377
Names and Identifiers
Synonyms
(R)-Simendan2-[2-[4-[(4R)-1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-propanedinitrileOR 1259R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrileLevosimendan(-)-OR-1259
IUPAC name
1-cyano-N-{4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}methanecarbohydrazonoyl cyanide
IUPAC Traditional name
levosimendan
Properties
Safety Information
GHS Hazard statements
H302-H312-H332
Risk Statements
20/21/22
RTECS
TY1570210
Safety Statements
36/37
Storage Temperature
room temp
German water hazard class
3
European Hazard Symbols
Harmful (Xn)GHS Precautionary statements
P280
GHS Pictograms
Acute toxicity (oral, dermal, inhalation), category 4
Skin irritation, category 2
Eye irritation, category 2
Skin sensitisation, category 1
Specific Target Organ Toxicity – Single exposure, category 3
GHS Signal Word
Warning
MSDS Link
Product Information
Empirical Formula (Hill Notation)
C14H12N6O
Purity
≥98% (HPLC)
Physical Property
Apperance
yellow powder
Solubility
DMSO: ≥20 mg/mL
Optical Rotation
[α]/D -500 to -650°, c = 0.5 in THF
Molecule Details
Biochem/physiol Actions
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data